Skip to content

H.R. 6227 · 118th Congress (2023–2025)

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 6227’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. David Schweikert (R-AZ-1)
Cosponsors
35 cosponsors

13 original · 22 later

21 R · 14 D

  1. Rep. Kelly Armstrong (R-ND)· Original · Nov 3, 2023
  2. Rep. Michael C. Burgess (R-TX-26)· Original · Nov 3, 2023
  3. Rep. Jim Costa (D-CA-21)· Original · Nov 3, 2023
  4. Rep. Juan Ciscomani (R-AZ-6)· Original · Nov 3, 2023
  5. Rep. Yadira Caraveo (D-CO-8)· Original · Nov 3, 2023
  6. Rep. Monica De La Cruz (R-TX-15)· Original · Nov 3, 2023
  7. Rep. Raúl M. Grijalva (D-AZ-7)· Original · Nov 3, 2023
  8. Rep. Ruben Gallego (D-AZ-3)· Original · Nov 3, 2023
  9. Rep. Mike Levin (D-CA-49)· Original · Nov 3, 2023
  10. Rep. Kevin McCarthy (R-CA-20)· Original · Nov 3, 2023
  11. Rep. Michelle Steel (R-CA-45)· Original · Nov 3, 2023
  12. Rep. Keith Self (R-TX-3)· Original · Nov 3, 2023
  13. Rep. David G. Valadao (R-CA-22)· Original · Nov 3, 2023
  14. Rep. Debbie Lesko (R-AZ-8)· Later · Nov 8, 2023
  15. Rep. Doug LaMalfa (R-CA-1)· Later · Nov 29, 2023
  16. Rep. Brittany Pettersen (D-CO-7)· Later · Nov 29, 2023
  17. Rep. Eric Swalwell (D-CA-14)· Later · Nov 29, 2023
  18. Rep. Melanie A. Stansbury (D-NM-1)· Later · Nov 29, 2023
  19. Rep. Jay Obernolte (R-CA-23)· Later · Dec 4, 2023
  20. Rep. Scott H. Peters (D-CA-50)· Later · Dec 5, 2023
  21. Rep. John Joyce (R-PA-13)· Later · Dec 13, 2023
  22. Rep. Kevin Mullin (D-CA-15)· Later · Dec 13, 2023
  23. Rep. Lizzie Fletcher (D-TX-7)· Later · Dec 19, 2023
  24. Rep. Susie Lee (D-NV-3)· Later · Dec 19, 2023
  25. Rep. Blake D. Moore (R-UT-1)· Later · Dec 19, 2023
  26. Rep. Mariannette Miller-Meeks (R-IA-1)· Later · Dec 19, 2023
  27. Rep. Stephanie I. Bice (R-OK-5)· Later · Jan 11, 2024
  28. Rep. Teresa Leger Fernandez (D-NM-3)· Later · Jan 11, 2024
  29. Rep. August Pfluger (R-TX-11)· Later · Feb 5, 2024
  30. Rep. Larry Bucshon (R-IN-8)· Later · Feb 23, 2024
  31. Rep. Troy Balderson (R-OH-12)· Later · Feb 23, 2024
  32. Rep. Andrea Salinas (D-OR-6)· Later · Feb 23, 2024
  33. Rep. Dan Crenshaw (R-TX-2)· Later · Mar 13, 2024
  34. Rep. Diana Harshbarger (R-TN-1)· Later · Mar 13, 2024
  35. Rep. Vince Fong (R-CA-20)· Later · Jul 22, 2024
Policy area
Health
Subjects
  • Cardiovascular and respiratory health
  • Drug safety, medical device, and laboratory regulation
  • Health promotion and preventive care
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Nov 3, 2023 – Nov 10, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Nov 3, 2023
  2. HouseHealthReferred Nov 10, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

    Official title · Introduced in House